Why Dosage Varies So Widely
The single most important thing to understand about boswellia dosing is that raw milligrams are almost meaningless without knowing the extract's standardization. A 100mg capsule of Aflapin (standardized to 20% AKBA) contains approximately 20mg of AKBA — the most pharmacologically active compound. A 1,000mg capsule of generic boswellia resin powder might contain negligible AKBA if it hasn't been properly extracted and standardized.
This explains why clinical trials show effective doses ranging from 100mg to over 1,000mg/day. The variable isn't just milligrams — it's the active compound content and the formulation's bioavailability.
Boswellic acids are highly lipophilic (fat-soluble). When taken on an empty stomach, absorption can be poor and highly variable between individuals. Studies show bioavailability increases significantly — in some cases 2–3× — when taken with a meal containing fat. This practical factor can matter as much as the dose itself.
Dosage by Extract Type
The following covers the dosage ranges used in clinical trials, organized by extract category.
Used in multiple trials with Aflapin and AprèsFlex. These extracts are standardized to 20% AKBA, providing 20mg AKBA per capsule. This is the lowest effective dose in the literature and only applies to these specific high-potency formulations.
Trials using 5-LOXIN (30% AKBA) typically used 100–200mg/day, providing 30–60mg AKBA. Effective results at 90 days in OA trials.
The most commonly studied range for standard standardized extracts. Typically taken in 2–3 divided doses with meals. Most clinical trials in OA and gut health used doses within this range.
The NCCIH notes up to 1,000mg/day has been used safely in trials lasting up to 6 months. Higher doses have been associated with adverse effects and should not be exceeded. More is not more effective — extract quality matters far more.
Dosage by Health Condition
Clinical trial protocols for specific conditions provide the best dosage guidance. The following reflects what has actually been studied.
| Condition | Extract Used | Dose | Duration | Evidence Level |
|---|---|---|---|---|
| Knee osteoarthritis | Aflapin / AprèsFlex (20% AKBA) | 100mg/day | 90 days–6 months | Strong |
| Knee osteoarthritis | 5-LOXIN (30% AKBA) | 100–200mg/day | 90 days | Strong |
| Knee osteoarthritis | Standard BSE (333mg, ~65% BAs) | 333mg 3× daily (1g total) | 8 weeks | Strong |
| Ulcerative colitis | H15 extract (BSE) | 350mg 3× daily | 6 weeks | Moderate |
| Crohn's disease | H15 extract (BSE) | 400mg 3× daily | 8 weeks | Moderate |
| Bronchial asthma | B. serrata extract | 300mg 3× daily | 6 weeks | Moderate |
| Chronic lower back pain | BSE + curcumin combination | Varies by formulation | 8 weeks | Moderate |
| Spondylitis pain | Full-spectrum BSE enhanced bioavailability | 400mg/day | 8 weeks | Emerging |
Timing and Administration
Take With Fat
This is the single most practically important dosing tip. Boswellic acids require bile secretion and dietary fat for optimal micellar solubilization and intestinal absorption. Studies consistently show meaningfully higher plasma levels of boswellic acids when supplements are taken with a meal containing fat (≥10g fat is sufficient). A glass of full-fat milk, a small handful of nuts, or any normal mixed meal qualifies.
Split Dosing
For standard extracts dosed at 300–1,000mg/day, dividing the dose into 2–3 administrations is generally recommended to maintain more consistent plasma levels of boswellic acids throughout the day. High-AKBA patented extracts at 100mg/day are typically taken as a single daily dose.
Consistency Matters
Boswellia is not a fast-acting analgesic. While some trials have observed meaningful pain reduction within 5 days, most clinical protocols are 8–12 weeks in duration. Daily consistent use is necessary to assess effectiveness for any chronic condition.
Cycling
There is no established evidence for cycling protocols with boswellia. Unlike some supplements, there is no known mechanism for tolerance development with continuous use. Long-term safety data extends to 6 months in most trials; data beyond this is limited.
Forms of Boswellia
Standardized Extract Capsules (Recommended)
The form used in virtually all clinical trials. Standardized to defined percentages of boswellic acids and/or AKBA. This is the only form for which dosage guidance from research is directly applicable. Always check the label for standardization percentage.
Crude Resin / Powder Capsules
Non-standardized boswellia resin powder. Highly variable in boswellic acid content. Clinical trial dosages cannot be reliably applied to these products. Generally not recommended when standardized extracts are available at comparable cost.
Phytosome Formulations
Newer phospholipid-bound formulations (boswellic acids complexed with phosphatidylcholine) are designed to improve absorption. Limited clinical data specifically for this form, but the rationale for improved bioavailability is sound. May allow for lower effective doses.
Topical Applications
Topical boswellia creams and gels exist but have a different evidence base and are not directly comparable to oral supplementation. Topical use avoids first-pass metabolism but boswellic acid penetration through intact skin is limited.
Essential Oil / Aromatherapy
Frankincense essential oil (typically from B. carterii or B. sacra) contains different active compounds (terpenes, incensole acetate) compared to oral boswellia extracts. The evidence base is separate, and aromatherapy applications are not equivalent to oral supplementation for systemic anti-inflammatory effects.
What to Look for on a Supplement Label
When evaluating a boswellia supplement, the following label elements are most important:
- Standardization statement — "Standardized to X% boswellic acids" or "containing X% AKBA"
- AKBA content specifically — AKBA is the most pharmacologically active compound; generic "boswellic acids" percentage does not guarantee meaningful AKBA
- Branded extract name — Aflapin, AprèsFlex, 5-LOXIN, Boswellin Super, and similar have published clinical trial data attached to them
- Third-party testing — NSF Certified for Sport, USP Verified, Informed Sport, or equivalent
- No artificial fillers or proprietary blends — Proprietary blends can mask low active ingredient content
Boswellia interacts with certain medications metabolized by cytochrome P450 enzymes (particularly CYP2C9, CYP3A4). It may also potentiate anticoagulant and antiplatelet drugs. Always discuss with your healthcare provider before starting boswellia, especially if you take any prescription medications. See our Drug Interactions page for details.
Special Populations
Pregnancy and Breastfeeding
Boswellia at medicinal doses should be avoided during pregnancy. Animal studies have raised concerns about potential effects on fetal development, and there is insufficient human safety data. The NCCIH notes that boswellia is likely safe in food amounts during pregnancy but explicitly cautions against medicinal doses. Breastfeeding safety is similarly unstudied.
Children
There is very limited safety data for boswellia supplementation in children. One case series noted potential adverse effects in pediatric glioma patients at high doses. Boswellia supplementation in children should not proceed without explicit pediatric medical guidance.
Liver Conditions
Because boswellic acids interact with hepatic drug transporters (OATP1B3) and CYP450 enzymes, individuals with liver disease or taking medications with hepatic metabolism should use particular caution and require medical supervision.
Pre-Surgery
Given potential effects on platelet function and drug metabolism, discontinue boswellia at least 2 weeks before any elective surgery and inform your surgical team of all supplements taken.